We are live on ! Find out more
APRE icon

Aprea Therapeutics
APRE

66 hedge funds and large institutions have $50.3M invested in Aprea Therapeutics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 16

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

3% more funds holding

Funds holding: 64 → 66 (+2)

1.54% less ownership

Funds ownership: 3.97% → 2.43% (-1.5%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

88% less capital invested

Capital invested by funds: $404M → $50.3M (-$354M)

Holders
66
Holders Change
+2
Holders Change %
+3.13%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
15
Increased
25
Reduced
16
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$9.63M
2
BlackRock
BlackRock
New York
+$8.09M
3
Artisan Partners
Artisan Partners
Wisconsin
+$5.39M
4
CCM
CAAS Capital Management
New York
+$4.38M
5
Two Sigma Investments
Two Sigma Investments
New York
+$3.78M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$45.1M
2
CCM
Consonance Capital Management
New York
-$35.1M
3
RG
Redmile Group
California
-$23.8M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$20.5M
5
5VM
5AM Venture Management
California
-$19.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
VVM
1
Versant Venture Management
California
$7.02M -$10.2M -21,395 -23%
5VM
2
5AM Venture Management
California
$6.78M -$19.9M -41,750 -38%
RG
3
Redmile Group
California
$6.24M -$23.8M -50,000 -44%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$6.21M -$45.1M -94,933 -60%
BlackRock
5
BlackRock
New York
$4.08M +$8.09M +17,004 +70%
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.69M +$2.53M +5,326 +17%
Artisan Partners
7
Artisan Partners
Wisconsin
$2.55M +$5.39M +11,335 +78%
Morgan Stanley
8
Morgan Stanley
New York
$2.33M +$9.63M +20,262 +598%
CS
9
Candriam SCA
Luxembourg
$1.78M +$3.05M +6,424 +55%
CCM
10
CAAS Capital Management
New York
$906K +$4.38M +9,204 New
SAM
11
Sectoral Asset Management
Quebec, Canada
$805K -$17.9M -37,600 -82%
Two Sigma Investments
12
Two Sigma Investments
New York
$781K +$3.78M +7,941 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$726K +$341K +718 +11%
Wellington Management Group
14
Wellington Management Group
Massachusetts
$707K +$2.32M +4,878 +212%
State Street
15
State Street
Massachusetts
$657K +$128K +270 +4%
PAI
16
Palo Alto Investors
California
$634K +$214K +449 +7%
Northern Trust
17
Northern Trust
Illinois
$559K -$109K -230 -4%
Millennium Management
18
Millennium Management
New York
$473K +$1.81M +3,803 +377%
Charles Schwab
19
Charles Schwab
California
$355K +$29.5K +62 +2%
GTCM
20
Gyon Technologies Capital Management
New Jersey
$206K +$994K +2,090 New
CIM
21
Coastal Investment Management
California
$206K +$998K +2,098 New
Walleye Trading
22
Walleye Trading
New York
$189K +$913K +1,920 New
AA
23
ALPS Advisors
Colorado
$188K +$268K +564 +42%
EAM
24
Erste Asset Management
Austria
$177K – – –
N
25
Nuveen
North Carolina
$169K +$138K +291 +20%
1
2 3 4

APRE Hedge Fund Activity: Q4 2020 in Review

66 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2020, worth a combined $50.3M — down 88% from $404M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new APRE positions and 13 closed out — a net gain of 2 holders — while 25 added to existing stakes and 16 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $9.63M. The largest seller was Fidelity Investments, cutting an estimated $45.1M.

  • 66 institutional investors held Aprea Therapeutics (APRE) as of Q4 2020, up from 64 in Q3 2020.
  • Funds reported $50.3M of Aprea Therapeutics stock for Q4 2020, down 88% quarter-over-quarter.
  • 15 funds opened new Aprea Therapeutics positions in Q4 2020 and 13 closed out, a net change of +2 holders.
  • The largest Aprea Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $9.63M added.
  • The largest Aprea Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $45.1M sold.

Based on aggregated 13F filings for Q4 2020.